Table 1.
Primary antibodies and IgG controls used in this study.
| Antibody | Host | Supplier/Cat#/RRIDb | Dilution |
|---|---|---|---|
| IB4 | LF/I21413 | 1.0 µg/ml | |
| CaV3.2a | Rabbit polyclonal | Alomone/ACC025/AB2039781 | 1:500 (IHC), 1:1000 (Wb) |
| ATF3 | Rabbit polyclonal | SCB/SC188 | 1:200 (IHC), 1:800 (Wb) |
| Iba1 | Rabbit polyclonal | Wako/019-19741 | 1:1000 (IHC) |
| GFAP | Rabbit polyclonal monoclonal | Dako/Z0334 | 1:500 (IHC) |
| Tubb3 | Mouse monoclonal monoclonal | SCB/sc-80016 | 1:400 (IHC), 1:1000 (Wb) |
| GAPDH | Mouse monoclonal monoclonal | Sigma/SAB1403850 | 1:2000 (WB) |
| IgG control | Mouse | LF/31903 | 1:100∼400 |
| IgG control | Rabbit | LF/MA5-16384 | 1:100∼1000 |
CaV3.2: T-type voltage-gated calcium channel 3.2; IB4: isolectin IB4; ATF3: activated transcriptional factor 3; Iba1: ionized calcium-binding adapter molecule 1; GFAP: glial fibrillary acidic protein; Tubb3: β3-Tubulin; GAPDH: glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase; IgG: immunoglobulin G; IHC: immunohistochemistry; WB: weight bearing.
aAntigenic peptide: CHVEGPQERARVAHS, corresponding to amino acid residues 581–595 of rat CaV3.2 intracellular loop between domains D1 and D2.
bLF, Life Technologies, Carlsbad, CA; Alomone, Alomone Labs, Jerusalem, Israel; SCB, Santa Cruz Biotechnology, Santa Cruz, CA; Wako, Richmond, VA; Dako: Carpinteria, California; Sigma, Sigma–Aldrich, St Louis, MO.